Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Receivables: 2017-2025

Historic Change in Receivables for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to $54,000.

  • UroGen Pharma's Change in Receivables fell 99.00% to $54,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year decrease of 131.13%. This contributed to the annual value of $4.9 million for FY2024, which is 77.40% up from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Change in Receivables is $54,000, which was up 390.91% from $11,000 recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Change in Receivables peaked at $5.4 million during Q3 2024, and registered a low of -$2.7 million during Q3 2023.
  • Over the past 3 years, UroGen Pharma's median Change in Receivables value was $11,000 (recorded in 2025), while the average stood at $636,273.
  • The largest annual percentage gain for UroGen Pharma's Change in Receivables in the last 5 years was 302.67% (2024), contrasted with its biggest fall of 509.00% (2024).
  • Quarterly analysis of 5 years shows UroGen Pharma's Change in Receivables stood at $3.9 million in 2021, then fell by 16.75% to $3.3 million in 2022, then declined by 20.73% to $2.6 million in 2023, then plummeted by 196.30% to -$2.5 million in 2024, then slumped by 99.00% to $54,000 in 2025.
  • Its Change in Receivables stands at $54,000 for Q3 2025, versus $11,000 for Q2 2025 and -$664,000 for Q1 2025.